Phillpotts R J, Wallace J, Tyrrell D A, Tagart V B
Antimicrob Agents Chemother. 1983 May;23(5):671-5. doi: 10.1128/AAC.23.5.671.
The therapeutic effect of intranasal 2-amino-1-(isopropylsulphonyl)-6-benzimidazole phenyl ketone oxime (enviroxime) against human rhinovirus type 9 was evaluated in a double-blind, placebo-controlled volunteer trial. Enviroxime given 6 times a day was well tolerated, producing a reduction in clinical evidence of infection which coincided with the start of medication (44 h after virus challenge). Although there was a statistically significant reduction in clinical score in the enviroxime group on day 5 after virus challenge, reductions in total clinical score accumulated during the trial and reductions in the quantity of nasal secretions were not significant. A separate analysis was performed on data from volunteers who did not have symptoms when medication began (and who might have been expected to benefit more from enviroxime therapy). No apparent enhancement of the effects of enviroxime could be demonstrated in this group.
在一项双盲、安慰剂对照的志愿者试验中，评估了鼻内给予2-氨基-1-（异丙基磺酰基）-6-苯并咪唑苯乙酮肟（恩韦肟）对9型人鼻病毒的治疗效果。每天给药6次的恩韦肟耐受性良好，用药后（病毒攻击后44小时）感染的临床证据有所减少。虽然在病毒攻击后第5天，恩韦肟组的临床评分有统计学意义的降低，但试验期间累积的总临床评分降低以及鼻分泌物量的减少并不显著。对用药开始时无症状（可能预期从恩韦肟治疗中获益更多）的志愿者的数据进行了单独分析。在该组中未显示出恩韦肟效果的明显增强。
